AR085915A1 - Cristal mixto de agomelatina (forma cristalina viii), sus metodos de preparacion, aplicaciones y composiciones farmaceuticas - Google Patents

Cristal mixto de agomelatina (forma cristalina viii), sus metodos de preparacion, aplicaciones y composiciones farmaceuticas

Info

Publication number
AR085915A1
AR085915A1 ARP120100969A ARP120100969A AR085915A1 AR 085915 A1 AR085915 A1 AR 085915A1 AR P120100969 A ARP120100969 A AR P120100969A AR P120100969 A ARP120100969 A AR P120100969A AR 085915 A1 AR085915 A1 AR 085915A1
Authority
AR
Argentina
Prior art keywords
preparation
agomelatine
crystal
mixed
methods
Prior art date
Application number
ARP120100969A
Other languages
English (en)
Inventor
Yu Huang
Xiong Yu
Hanbin Shan
Qing Long
Xueyan Zhu
Zhedong Yuan
Original Assignee
Servier Lab
Shanghai Inst Pharm Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Shanghai Inst Pharm Industry filed Critical Servier Lab
Publication of AR085915A1 publication Critical patent/AR085915A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente proporciona un cristal mixto de agomelatina (forma VIII), sus métodos de preparación, su aplicación y sus composiciones farmacéuticas en las que el cristal mixto es principalmente agomelatina de forma VI. La estabilidad del tipo mixto y la buena reproducibilidad y su método de preparación son mejores que en la mayoría de los informes existentes respecto de estabilidad y solubilidad del polimorfo VI. Por lo tanto, la presente proporciona una forma VIII que resulta ventajosa en la preparación.Reivindicación 2: Un cristal mixto de agomelatina de acuerdo con el modelo de difracción por rayos X, caracterizado por ángulo 2q, espacio interplanar d, e intensidad relativa: @@@@@@@@@
ARP120100969A 2011-03-23 2012-03-23 Cristal mixto de agomelatina (forma cristalina viii), sus metodos de preparacion, aplicaciones y composiciones farmaceuticas AR085915A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011100706340A CN102690209A (zh) 2011-03-23 2011-03-23 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物

Publications (1)

Publication Number Publication Date
AR085915A1 true AR085915A1 (es) 2013-11-06

Family

ID=46855965

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100969A AR085915A1 (es) 2011-03-23 2012-03-23 Cristal mixto de agomelatina (forma cristalina viii), sus metodos de preparacion, aplicaciones y composiciones farmaceuticas

Country Status (30)

Country Link
US (1) US20140088197A1 (es)
EP (1) EP2690088B1 (es)
JP (1) JP6203171B2 (es)
KR (1) KR20130136546A (es)
CN (2) CN102690209A (es)
AR (1) AR085915A1 (es)
AU (1) AU2012231548B2 (es)
BR (1) BR112013024022A2 (es)
CA (1) CA2829690C (es)
CY (1) CY1118751T1 (es)
DK (1) DK2690088T3 (es)
EA (1) EA023278B1 (es)
ES (1) ES2626030T3 (es)
GE (1) GEP201606567B (es)
HK (1) HK1193086A1 (es)
HR (1) HRP20170575T1 (es)
HU (1) HUE034329T2 (es)
LT (1) LT2690088T (es)
MA (1) MA34959B1 (es)
MD (1) MD4484C1 (es)
ME (1) ME02731B (es)
MX (1) MX355551B (es)
MY (1) MY166444A (es)
PL (1) PL2690088T3 (es)
PT (1) PT2690088T (es)
RS (1) RS55918B1 (es)
SG (1) SG193305A1 (es)
SI (1) SI2690088T1 (es)
WO (1) WO2012126386A1 (es)
ZA (1) ZA201306761B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
EP3027588B1 (fr) * 2013-07-29 2020-04-01 Les Laboratoires Servier Complexes d'agomélatine et d'acides sulfoniques, procédé de leur préparation et compositions pharmaceutiques qui les contiennent
CN104529804A (zh) * 2014-12-11 2015-04-22 连云港金康医药科技有限公司 阿戈美拉汀的新晶型
PL3075724T3 (pl) 2015-03-31 2023-12-27 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Stała postać agomelatyny
EP3466923A1 (en) * 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Process for the preparation of agomelatine in crystalline form

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7498466B2 (en) * 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101723844A (zh) * 2009-11-21 2010-06-09 浙江华海药业股份有限公司 一种阿戈美拉汀晶形b、它的制备方法和包含它的药物组合物
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
EP2319827A1 (en) * 2009-11-09 2011-05-11 Ratiopharm GmbH Process for the production of polymorph form I of agomelatine
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN101792400B (zh) * 2010-03-16 2013-01-30 华东师范大学 一种阿戈美拉汀的合成方法
CL2011001405A1 (es) * 2010-06-10 2012-03-30 Gador S A Conicet Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
WO2012046253A2 (en) * 2010-10-08 2012-04-12 Msn Laboratories Limited Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms
CN102452952A (zh) * 2010-11-03 2012-05-16 天津药物研究院 一种高纯度的i型阿戈美拉汀晶体制备方法

Also Published As

Publication number Publication date
MD4484B1 (ro) 2017-05-31
LT2690088T (lt) 2017-04-10
US20140088197A1 (en) 2014-03-27
EA023278B1 (ru) 2016-05-31
KR20130136546A (ko) 2013-12-12
MY166444A (en) 2018-06-27
GEP201606567B (en) 2016-11-10
CA2829690C (en) 2016-08-09
AU2012231548B2 (en) 2015-11-19
PL2690088T3 (pl) 2017-09-29
ME02731B (me) 2017-10-20
CA2829690A1 (en) 2012-09-27
ZA201306761B (en) 2014-05-25
HRP20170575T1 (hr) 2017-06-30
BR112013024022A2 (pt) 2016-12-06
WO2012126386A1 (zh) 2012-09-27
EP2690088B1 (en) 2017-02-22
EA201301065A1 (ru) 2014-02-28
JP6203171B2 (ja) 2017-09-27
CN103476743A (zh) 2013-12-25
PT2690088T (pt) 2017-03-20
SG193305A1 (en) 2013-10-30
EP2690088A4 (en) 2014-09-17
RS55918B1 (sr) 2017-09-29
EP2690088A1 (en) 2014-01-29
SI2690088T1 (sl) 2017-06-30
MD20130074A2 (en) 2014-03-31
MX2013010634A (es) 2013-10-07
CN103476743B (zh) 2015-02-25
MA34959B1 (fr) 2014-03-01
MD4484C1 (ro) 2017-12-31
MX355551B (es) 2018-04-23
HK1193086A1 (en) 2014-09-12
DK2690088T3 (en) 2017-06-06
ES2626030T3 (es) 2017-07-21
CY1118751T1 (el) 2017-07-12
NZ615714A (en) 2016-03-31
CN102690209A (zh) 2012-09-26
HUE034329T2 (en) 2018-02-28
AU2012231548A1 (en) 2013-10-03
JP2014516921A (ja) 2014-07-17

Similar Documents

Publication Publication Date Title
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
CR20140493A (es) Compuestos novedosos
UY35469A (es) Moduladores de p2x7
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
UY34100A (es) INMUNOCONJUGADOS DEL PROFARMACO seco-MGBA, COMPOSICIONES Y MÉTODOS PARA PREPARARLOS, Y SUS USOS
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
CU23824A3 (es) Compuestos tricíclicos y sus composiciones
UY33469A (es) Composiciones y metodos para modular la via de señalizacion de wnt
AR085915A1 (es) Cristal mixto de agomelatina (forma cristalina viii), sus metodos de preparacion, aplicaciones y composiciones farmaceuticas
UY33800A (es) Compuestos reguladores del crecimiento de plantas
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
CR20120287A (es) Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112014018032A2 (pt) método para produzir uma composição
BR112014013098A2 (pt) composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
CO7350641A2 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
BR112014014939A2 (pt) composição de tratamento de sementes
BR112017005856A2 (pt) reação de carboxilação de fluxo contínuo
CU20140103A7 (es) Compuestos de cromano sustituidos como modulares del receptor sensible al calcio
UY33794A (es) Inhibidores diméricos de las iap
UY33236A (es) Inhibidores dimericos de las iap
BR112017000417A2 (pt) processo para preparação de fenil alcanos substituídos
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
DOP2016000211A (es) Pirazinas moduladoras de gpr6

Legal Events

Date Code Title Description
FB Suspension of granting procedure